CHIP (325 mg/M2), a second generation cisplatin derivative, was administered intravenously every 3 weeks to 85 pediatric patients with recurrent sarcomas (19), osteosarcomas (20), neuroblastoma (23), germ cell tumors (10), and other malignant tumors (7). Thirty-eight of them had been previously exposed to cisplatin.
Partial remissions were only observed in 3 of 23 (13% SE = 7%) patients having neuroblastoma. Severe thrombocytopenia (65%) and neutropenia (35%) were the dose limiting factors.
|Number of pages||4|
|Journal||Investigational new drugs|
|Publication status||Published - Jul-1992|
- PEDIATRIC MALIGNANCIES
- RECURRENT PEDIATRIC MALIGNANT SOLID TUMORS
- PHASE-II STUDY